Posts Tagged ‘Stomach’

Gastroduodenal Crohns Disease

02.27.10

In anatomy, the gastroduodenal artery is a small blood vessel in the abdomen.It supplies blood to the pylorus (distal part of the stomach) and the proximal part of the duodenum.It arises from the common hepatic artery and terminates in a bifurcation, when it splits into the right gastroepiploic artery and the anterior superior pancreaticoduodenal artery.

Crohns disease involving the gastric outlet and proximal duodenum, resulting in gastric outlet obstruction. Image on the right shows a view of the stricture as seen through a translucent dilating balloon, which has been inflated in the stricture.

1. Melatonin protection against ethanol-induced gastroduodenal injury was investigated in duodenumligated rats.
2. Melatonin, injected i.p. 30 min before administration of 1 ml of absolute ethanol, given by gavage, significantly decreased ethanol-induced macroscopic, histological and biochemical changes in the gastroduodenal mucosa.
3. Ethanol-induced lesions were detectable as haemorrhagic streaks. Ethanol administration damaged 36% and 25% of the total gastric and duodenal surface, respectively.

Melatonin treatment reduced ethanol-induced gastric and duodenal damage to 14% and 8%, respectively. When indomethacin was given together with ethanol, the gastric damaged area was 44% of the total surface, while the duodenal damaged area was 35%; melatonin administration reduced the damage to only 13% of the total gastric surface and to 12% of total duodenal surface.

4. Both stomach and duodenum of ethanol-treated animals showed polymorphonuclear leukocyte (PMN) infiltration. The number of PMN increased more than 600 and 200 times in stomach and duodenum, respectively, following ethanol administration. Melatonin treatment reduced ethanol-induced PMN infiltration by 38% in the stomach and 20% in the duodenum. In indomethacin-ethanol-treated rats, the number of PMN increased by 875% compared to control group in the stomach and by 264% in duodenum. Melatonin administration reduced the indomethacin-ethanol-induced PMN rise by 57% in the stomach and 40% in the duodenum.

5. Gastroduodenal total glutathione (tGSH) concentration and glutathione reductase (GSSG-Rd) activity were significantly reduced following ethanol and indomethacin-ethanol administration. Melatonin ameliorated both the decrease in tGSH concentration as well as the reduction of GSSG-Rd activity elicited by ethanol both in the stomach and duodenum; melatonin was effective against indomethacin-ethanol-induced damage only in the stomach.

6. Ethanol-induced gastroduodenal damage is believed to be mediated by the generation of free radicals. Recently, a number of in vivo and in vitro experiments have shown melatonin to be an effective antioxidant and free radical scavenger; thus, we conclude that the protection by melatonin against ethanol-induced gastroduodenal injury is due, at least in part, to its radical scavenging activity.

Possibly related posts: (automatically generated)

Crohns Disease Statistics

12.31.09

Crohn’s Disease is a chronic inflammation of the digestive track.

The digestive track covers the following:
•    Mouth
•    Esophagus
•    Stomach
•    Small Intestine
•    Large Intestine
•    Rectum
•    Anus

Crohn’s can affect any of those areas, but most commonly attacks the ileum or the lower small intestine. The swelling of the affected area will cause pain and diarrhea.

Statistics
Crohn’s can be found in both men and women. It may run in families, 20% of people diagnosed with the disease have a blood relative with some form of inflammatory bowel disease. It is usually diagnosed between the ages of 20 to 30, although people of all ages can suffer from Crohn’s. People of Jewish heritage have a greater risk of developing the disease while people of African American heritage have less of a risk.

Prevalance of Crohn’s disease: 500,000 Americans

Prevalance Rate: approx 1 in 544 or 0.18% or 500,000 people in

Hospitalization statistics for Crohn’s disease: The following are statistics from various sources about hospitalizations and Crohn’s disease:
•    0.17% (21,634) of hospital consultant episodes were for crohn’s disease in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    82% of hospital consultant episodes for crohn’s disease required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    42% of hospital consultant episodes for crohn’s disease were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    58% of hospital consultant episodes for crohn’s disease were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    35% of hospital consultant episodes for crohn’s disease required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    9.6 days was the mean length of stay in hospitals for crohn’s disease in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    6 days was the median length of stay in hospitals for crohn’s disease in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    39 was the mean age of patients hospitalised for crohn’s disease in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    78% of hospital consultant episodes for crohn’s disease occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    5% of hospital consultant episodes for crohn’s disease occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    36% of hospital consultant episodes for crohn’s disease were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
•    0.18% (93,538) of hospital bed days were for crohn’s disease in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)